Annexon, Inc. (NASDAQ:ANNX) CEO Douglas Love Sells 7,500 Shares of Stock

Annexon, Inc. (NASDAQ:ANNX) CEO Douglas Love sold 7,500 shares of the business’s stock in a transaction on Thursday, September 16th. The stock was sold at an average price of $22.05, for a total value of $165,375.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Shares of ANNX opened at $21.25 on Tuesday. Annexon, Inc. has a one year low of $15.52 and a one year high of $38.01. The firm has a market capitalization of $814.56 million, a P/E ratio of -7.70 and a beta of 1.39. The business has a fifty day moving average of $19.82 and a 200 day moving average of $22.55.

Annexon (NASDAQ:ANNX) last issued its quarterly earnings data on Sunday, August 15th. The company reported ($0.82) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.69) by ($0.13). On average, research analysts anticipate that Annexon, Inc. will post -3 earnings per share for the current fiscal year.

Large investors have recently added to or reduced their stakes in the business. E Fund Management Co. Ltd. bought a new stake in Annexon during the first quarter valued at about $27,000. HighMark Wealth Management LLC bought a new stake in Annexon during the second quarter valued at about $33,000. O Shaughnessy Asset Management LLC bought a new stake in Annexon during the second quarter valued at about $51,000. Royal Bank of Canada grew its holdings in Annexon by 484.7% during the first quarter. Royal Bank of Canada now owns 2,216 shares of the company’s stock valued at $62,000 after purchasing an additional 1,837 shares during the period. Finally, SG Americas Securities LLC bought a new stake in Annexon during the first quarter valued at about $154,000.

Separately, Zacks Investment Research lowered Annexon from a “hold” rating to a “sell” rating in a report on Friday, August 20th.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune and neurodegenerative diseases. It focuses on the treatment of body, brain, and eye disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration.

Read More: What’s a Black Swan?

Insider Buying and Selling by Quarter for Annexon (NASDAQ:ANNX)

Receive News & Ratings for Annexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annexon and related companies with MarketBeat.com's FREE daily email newsletter.